382 related articles for article (PubMed ID: 29551455)
1. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
[TBL] [Abstract][Full Text] [Related]
2. [Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies].
Deyev SM; Lebedenko EN
Mol Biol (Mosk); 2017; 51(6):907-926. PubMed ID: 29271956
[TBL] [Abstract][Full Text] [Related]
3. Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.
Trapani D; Katrini J; Curigliano G
JAMA Oncol; 2024 May; 10(5):563-564. PubMed ID: 38483383
[TBL] [Abstract][Full Text] [Related]
4. Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells.
Kojima R; Aubel D; Fussenegger M
Curr Opin Chem Biol; 2015 Oct; 28():29-38. PubMed ID: 26056952
[TBL] [Abstract][Full Text] [Related]
5. Theranostic barcoded nanoparticles for personalized cancer medicine.
Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
[TBL] [Abstract][Full Text] [Related]
7. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
8. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
[TBL] [Abstract][Full Text] [Related]
9. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
Paliard X; Rixe O
Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
[TBL] [Abstract][Full Text] [Related]
10. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
Agur Z; Elishmereni M; Foryś U; Kogan Y
Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
[TBL] [Abstract][Full Text] [Related]
11. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment.
Jasim SA; Farber IM; Noraldeen SAM; Bansal P; Alsaab HO; Abdullaev B; Alkhafaji AT; Alawadi AH; Hamzah HF; Mohammed BA
Microvasc Res; 2024 Jul; 154():104691. PubMed ID: 38703993
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Nanoparticles in Cancer Theranostics.
Gobbo OL; Sjaastad K; Radomski MW; Volkov Y; Prina-Mello A
Theranostics; 2015; 5(11):1249-63. PubMed ID: 26379790
[TBL] [Abstract][Full Text] [Related]
14. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
15. Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting.
Layek B; Sadhukha T; Panyam J; Prabha S
Mol Cancer Ther; 2018 Jun; 17(6):1196-1206. PubMed ID: 29592881
[TBL] [Abstract][Full Text] [Related]
16. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
17. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
[TBL] [Abstract][Full Text] [Related]
18. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
[TBL] [Abstract][Full Text] [Related]
19. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
Zhu L; Zhou Z; Mao H; Yang L
Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
[TBL] [Abstract][Full Text] [Related]
20. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
